Page last updated: 2024-11-02

oxyphenbutazone and Clinically Isolated CNS Demyelinating Syndrome

oxyphenbutazone has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 1 studies

Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)
oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tzonos, T1
Götze, P1

Other Studies

1 other study available for oxyphenbutazone and Clinically Isolated CNS Demyelinating Syndrome

ArticleYear
[The triethyltin sulfate-induced brain edema in rats and its response to oxyphenbutazone].
    Deutsche Zeitschrift fur Nervenheilkunde, 1969, Volume: 196, Issue:2

    Topics: Adenosine Triphosphatases; Animals; Brain Edema; Demyelinating Diseases; Enzyme Repression; Ethanol;

1969